Stock listing
gettex:3920 Spyre Therapeutics, Inc. Aktie
German listing (gettex) of Spyre Therapeutics, Inc. · home listing NASDAQ:SYRE
Follow Spyre Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SYRE
$93.47 USD -7.99 (-7.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SYRE
- Day range
- $93.22 – $99.56 USDNov 20, 2026
- Volume
- 805,350 sharesNov 20, 2026
- Market cap
- $8.88B USDAt the close on Nov 20, 2026 · price × 94.97M shares outstanding
- 52-week range
- $23.01 – $110.64 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $114.8M USDMedian day 1.10M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SYRE · Home | $93.47 USD | -7.99 (-7.9%) | 805,350 | $95.93 | $99.56 | $93.22 | $101.46 | Close on Nov 20, 2026 |
| Frankfurt:3920 | €87.00 EUR | -5.50 (-5.9%) | — | €87.00 | €87.00 | €87.00 | €92.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SYRE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $93.47 | -7.99 | -7.9% | $95.93 | $99.56 | $93.22 | 805,350 | |
| $101.46 | +7.65 | +8.2% | $93.61 | $102.72 | $93.51 | 1,371,847 | |
| $93.81 | -5.56 | -5.6% | $98.70 | $100.04 | $92.98 | 1,102,434 | |
| $99.37 | -4.63 | -4.5% | $102.26 | $106.20 | $98.81 | 824,685 | |
| $104.00 | +1.09 | +1.1% | $102.33 | $104.50 | $100.49 | 746,230 | |
| $102.91 | -3.91 | -3.7% | $105.21 | $105.28 | $101.40 | 985,828 | |
| $106.82 | +2.34 | +2.2% | $104.71 | $107.87 | $103.72 | 894,432 | |
| $104.48 | -4.52 | -4.1% | $106.95 | $109.15 | $103.19 | 1,003,963 | |
| $109.00 | +5.14 | +4.9% | $105.59 | $110.64 | $104.41 | 1,393,580 | |
| $103.86 | +7.27 | +7.5% | $98.35 | $104.25 | $97.29 | 1,630,339 | |
| $96.59 | -2.45 | -2.5% | $98.38 | $98.75 | $93.83 | 1,160,382 | |
| $99.04 | -0.23 | -0.2% | $99.00 | $100.00 | $92.77 | 1,470,188 | |
| $99.27 | +3.76 | +3.9% | $97.04 | $100.00 | $96.51 | 902,838 | |
| $95.51 | -1.05 | -1.1% | $97.11 | $98.00 | $93.83 | 749,263 | |
| $96.56 | -2.40 | -2.4% | $96.78 | $98.96 | $94.68 | 658,464 | |
| $98.96 | -0.79 | -0.8% | $99.71 | $100.42 | $97.96 | 567,627 | |
| $99.75 | +0.705 | +0.7% | $98.39 | $100.06 | $97.55 | 724,412 | |
| $99.05 | +6.135 | +6.6% | $93.00 | $99.24 | $92.95 | 944,289 | |
| $92.91 | +2.58 | +2.9% | $91.54 | $94.19 | $90.42 | 637,157 | |
| $90.33 | -2.00 | -2.2% | $90.71 | $91.90 | $88.69 | 503,000 | |
| $92.33 | -0.62 | -0.7% | $92.95 | $94.57 | $91.27 | 802,900 | |
| $92.95 | +1.55 | +1.7% | $92.78 | $95.17 | $92.32 | 1,153,100 | |
| $91.40 | +6.68 | +7.9% | $85.12 | $93.22 | $85.08 | 1,708,500 | |
| $84.72 | +4.82 | +6.0% | $82.29 | $86.05 | $80.94 | 1,272,000 | |
| $79.90 | -0.20 | -0.2% | $80.21 | $80.52 | $78.13 | 1,273,300 | |
| $80.10 | +1.47 | +1.9% | $76.87 | $80.88 | $76.87 | 1,148,000 | |
| $78.63 | -1.82 | -2.3% | $80.13 | $82.45 | $77.95 | 1,624,600 | |
| $80.45 | -5.45 | -6.3% | $85.12 | $85.32 | $80.45 | 1,441,000 | |
| $85.90 | +0.21 | +0.2% | $86.30 | $86.62 | $84.21 | 873,900 | |
| $85.69 | +5.79 | +7.2% | $79.90 | $86.22 | $78.73 | 1,116,400 | |
| $79.90 | -0.95 | -1.2% | $79.58 | $80.91 | $77.05 | 2,326,700 | |
| $80.85 | +0.74 | +0.9% | $78.91 | $82.22 | $78.00 | 2,719,300 | |
| $80.11 | -12.61 | -13.6% | $92.08 | $92.08 | $79.36 | 4,252,300 | |
| $92.72 | -0.47 | -0.5% | $93.02 | $95.01 | $89.49 | 642,800 | |
| $93.19 | +3.26 | +3.6% | $91.16 | $95.27 | $90.48 | 1,235,000 | |
| $89.93 | +0.90 | +1.0% | $89.13 | $94.06 | $87.25 | 1,662,600 | |
| $89.03 | +4.31 | +5.1% | $88.64 | $95.08 | $88.00 | 2,096,000 | |
| $84.72 | -1.07 | -1.2% | $85.09 | $86.64 | $83.26 | 1,053,200 | |
| $85.79 | +0.10 | +0.1% | $84.72 | $87.12 | $84.00 | 1,045,400 | |
| $85.69 | -1.40 | -1.6% | $88.10 | $88.10 | $85.63 | 560,100 | |
| $87.09 | -1.08 | -1.2% | $87.46 | $87.46 | $82.93 | 1,729,600 | |
| $88.17 | -3.80 | -4.1% | $91.56 | $91.56 | $86.30 | 918,800 | |
| $91.97 | -0.06 | -0.1% | $91.53 | $93.58 | $89.90 | 1,223,400 | |
| $92.03 | +1.78 | +2.0% | $91.07 | $94.06 | $89.65 | 1,448,700 | |
| $90.25 | -2.43 | -2.6% | $92.82 | $93.34 | $89.85 | 3,357,100 | |
| $92.68 | +1.51 | +1.7% | $92.86 | $95.19 | $91.14 | 1,438,900 | |
| $91.17 | +0.22 | +0.2% | $91.38 | $93.07 | $90.48 | 1,257,600 | |
| $90.95 | +0.15 | +0.2% | $90.82 | $91.07 | $88.47 | 858,500 | |
| $90.80 | +0.20 | +0.2% | $90.21 | $91.40 | $89.43 | 1,101,200 | |
| $90.60 | +1.89 | +2.1% | $90.00 | $91.41 | $87.89 | 886,100 | |
| $88.71 | +1.78 | +2.0% | $85.56 | $88.72 | $85.26 | 902,400 | |
| $86.93 | -3.86 | -4.3% | $88.07 | $89.57 | $86.85 | 1,005,800 | |
| $90.79 | +1.81 | +2.0% | $85.00 | $92.10 | $85.00 | 1,248,800 | |
| $88.98 | +1.73 | +2.0% | $86.45 | $89.18 | $84.68 | 803,800 | |
| $87.25 | +0.20 | +0.2% | $86.71 | $87.90 | $85.78 | 1,054,200 | |
| $87.05 | -1.45 | -1.6% | $88.05 | $90.18 | $84.00 | 1,361,500 | |
| $88.50 | -0.83 | -0.9% | $87.06 | $90.00 | $85.00 | 1,429,000 | |
| $89.33 | -1.03 | -1.1% | $89.15 | $90.97 | $86.40 | 1,913,200 | |
| $90.36 | -3.255 | -3.5% | $91.75 | $93.39 | $89.45 | 1,266,500 | |
| $93.62 | +0.01 | 0.0% | $93.61 | $94.95 | $91.25 | 1,165,300 | |
| $93.61 | -13.75 | -12.8% | $92.41 | $96.22 | $90.60 | 3,114,200 | |
| $107.36 | +0.71 | +0.7% | $109.02 | $110.15 | $106.94 | 923,600 | |
| $106.65 | +0.16 | +0.2% | $106.49 | $108.02 | $104.94 | 640,600 | |
| $106.49 | -1.30 | -1.2% | $108.85 | $110.00 | $105.71 | 1,014,900 | |
| $107.79 | -1.13 | -1.0% | $106.60 | $108.18 | $104.56 | 700,600 |
Splits
1 split · NASDAQ:SYRE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation |
- Ticker
- gettex:3920
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Spyre Therapeutics to Participate in Upcoming Investor Conferences
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 36 slides
Latest news
Spyre Therapeutics to Participate in Upcoming Investor Conferences
Nov 10, 2026
Closed $104.48 (-4.1%) on Nov 10, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
Nov 6, 2026
Closed $109.00 (+4.9%) on Nov 9, 2026
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 3, 2026
Closed $99.04 (-0.2%) on Nov 4, 2026
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
Oct 18, 2026
Closed $84.72 (+6.0%) on Oct 19, 2026
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Oct 5, 2026
Closed $80.11 (-13.6%) on Oct 6, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Oct 5, 2026
Closed $80.11 (-13.6%) on Oct 6, 2026
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Sep 8, 2026
Closed $90.79 (+2.0%) on Sep 8, 2026
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Sep 3, 2026
Closed $88.98 (+2.0%) on Sep 4, 2026
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Aug 25, 2026
Closed $93.61 (-12.8%) on Aug 26, 2026
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
Aug 10, 2026
Closed $105.33 (+0.4%) on Aug 10, 2026
Spyre Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 148 in all · newest Nov 10, 2026 · oldest 2019
- Decks
- 32 decks · latest October 2026
Where Spyre Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SYRE · Home listing | NASDAQ | United States | USD |
| LS Exchange:A3D4LY | LS Exchange | Germany | EUR |
| BOATS:SYRE | BOATS | United States | USD |
| Lang & Schwarz:A3D4LY | Lang & Schwarz | Germany | EUR |
| Dusseldorf:3920 | Dusseldorf | Germany | EUR |
| Tradegate:3920 | Tradegate | Germany | EUR |
| Stuttgart:3920 | Stuttgart | Germany | EUR |
| Frankfurt:3920 | Frankfurt | Germany | EUR |
| gettex:3920 · This page | gettex | Germany | EUR |
| Munich:3920 | Munich | Germany | EUR |
| Xetra:3920 | Xetra | Germany | EUR |
Valuation
EV/sales 86.3× against a median of 17.5×: 7th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $7.80B USD
- P/E
- Loss
- EV/sales
- 86.3×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 8.4×
- Gross margin
- Not reported
- Operating margin
- −276.4%
- Net margin
- −291.6%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.71
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. · NASDAQ:SYRE | US$8.88B | US$7.80B | n/a | 86.3× | n/a | 8.4× | −291.6% | 0.0× | 1.71 |
| Halozyme Therapeutics, Inc. · NASDAQ:HALO | US$10.41B | US$12.59B | 21.5× | 7.0× | 18.2× | n/a | 26.9% | n/a | 0.63 |
| Kymera Therapeutics, Inc. · NASDAQ:KYMR | US$9.84B | US$8.87B | n/a | 86.8× | n/a | 6.1× | −341.8% | 0.0× | 0.92 |
| TG Therapeutics, Inc. · NASDAQ:TGTX | US$9.70B | US$9.94B | 91.4× | 11.1× | 51.5× | 16.9× | 11.8% | 1.3× | 0.70 |
| Krystal Biotech, Inc. · NASDAQ:KRYS | US$9.15B | US$8.24B | 40.6× | 17.5× | 35.3× | 6.4× | 47.9% | 0.0× | 0.69 |
| Alteogen Inc. · KRX:196170 | US$9.01B | US$8.68B | 63.2× | 46.0× | 91.9× | 22.6× | 75.5% | 0.0× | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H · HKEX:6990 | US$8.99B | US$8.28B | 472× | 25.1× | 337× | 11.2× | 5.8% | 0.0× | n/a |
| Vaxcyte, Inc. · NASDAQ:PCVX | US$8.77B | US$7.70B | n/a | n/a | n/a | 3.5× | n/a | 0.1× | 1.24 |
| Praxis Precision Medicines, Inc. · NASDAQ:PRAX | US$8.40B | US$7.65B | n/a | n/a | n/a | 6.7× | n/a | 0.0× | 1.45 |
| Summit Therapeutics Inc. · NASDAQ:SMMT | US$7.96B | US$7.33B | n/a | n/a | n/a | 14.1× | n/a | 0.0× | 1.91 |
| Protagonist Therapeutics, Inc. · NASDAQ:PTGX | US$7.92B | US$7.13B | 23.1× | 12.9× | 22.0× | 7.3× | 62.0% | 0.0× | 0.93 |
| Median of the others | US$9.00B | US$8.26B | 52.0× | 17.5× | 43.4× | 7.3× | 26.9% | 0.0× | 0.93 |
Forecasts
16 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 123.87 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.04 · 13 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Cameron Turtle | Chief Executive Officer |
| Heidy King-Jones | Chief Legal Officer and Corporate Secretary |
| Eric McIntyre | SVP of Finance and Investor Relations |
Board
| Director | Role |
|---|---|
| Jeff Albers | Chair of the Compensation Committee |
| Laurie Stelzer | Chair of the Audit Committee |
| Mark McKenna | Board Member |
| Michael Henderson | Board Member |
| Sandra Milligan | Chair of the Nominating and Corporate Governance Committee |
| Tomas Kiselak | Member of the Compensation Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · After close | −0.2% |
| Q2 2026 | Aug 4, 2026 · After close | −0.6% |
| Q1 2026 | May 7, 2026 | +2.8% |
| Q4 2025 | Feb 19, 2026 · After close | +14.3% |
| Q3 2025 | Nov 4, 2025 · After close | −0.6% |
| Q2 2025 | Aug 5, 2025 · After close | −5.4% |
| Q1 2025 | May 8, 2025 · After close | +9.6% |
| Q4 2024 | Feb 26, 2025 · After close | −3.3% |
| Q3 2024 | Nov 7, 2024 · After close | +5.0% |
| Q2 2024 | Aug 7, 2024 · After close | +2.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +4.9% |
| Q4 2023 | Feb 29, 2024 · After close | +9.0% |
| Q3 2023 | Nov 9, 2023 · After close | +0.2% |
| Q2 2023 | Aug 11, 2023 · Before open | −4.8% |
| Q1 2023 | May 11, 2023 · Before open | −3.7% |
| Q4 2022 | Mar 2, 2023 | −0.3% |
| Q3 2022 | Nov 3, 2022 · Before open | −6.6% |
| Q2 2022 | Aug 4, 2022 · Before open | +6.4% |
| Q1 2022 | May 5, 2022 | −10.9% |
| Q4 2021 | Mar 8, 2022 · Before open | +3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 36 slides | October 2026 |
| Technical Presentation (April 2026) | Technical | 31 slides | Apr 13, 2026 |
| Investor Presentation (January 2026) | Investor deck | 38 slides | Jan 12, 2026 |
| Technical Presentation (June 2025) | Technical | 36 slides | Jun 17, 2025 |
| Investor Presentation (January 2025) | Investor deck | 58 slides | Jan 13, 2025 |
| Corporate Update (November 2024) | Corporate update | 31 slides | Nov 12, 2024 |
| Investor Presentation (October 2024) | Investor deck | 49 slides | Oct 15, 2024 |
| Aeglea BioTherapeutics — Investor Presentation (October 2023) | Investor deck | 38 slides | Oct 24, 2023 |
| Aeglea BioTherapeutics — Investor Presentation (September 2023) | Investor deck | 56 slides | Sep 8, 2023 |
| Aeglea BioTherapeutics — Merger or Acquisition (June 2023) | Merger or acquisition | 50 slides | Jun 23, 2023 |
All 32 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$400M raised · US$85 a share · Jefferies +4 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), Stifel (co-lead), LifeSci Capital Use of proceeds: To fund a pivotal program in hidradenitis suppurativa with SPY072, its TL1A monotherapy | Nov 3, 2026 |
| At-the-market programme of common stock Tranche closed: US$18M raised | Nov 3, 2026 |
| Public offering of common stock Made bigger: about US$403M · US$62 a share · Jefferies LLC +4 Dealers: Jefferies LLC (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, LLC (co-lead), LifeSci Capital LLC | Apr 14, 2026 |
| Public offering of common stock Closed: US$316.2M raised · US$18.5 a share · Jefferies LLC +4 Dealers: Jefferies LLC (co-lead), TD Securities (USA) LLC (co-lead), Leerink Partners LLC (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), Wedbush Securities Inc. | Oct 15, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Aeglea BioTherapeutics, Inc. Priced at US$10.00 a share on Apr 6, 2016.
- Price
- US$10.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$50 million
- Underwriters' option
- Up to 750,000 more shares
- Underwriters
- UBS Investment Bank, BMO Capital Markets, Wells Fargo Securities, Needham & Company · In the order on the cover
- Shares delivered
- On or about Apr 12, 2016
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 6, 2015 |
| Filed publicly | Jun 16, 2015 |
| Amended 6 times | Newest Apr 7, 2016 |
| Shares registered with an exchange | Mar 28, 2016 |
| Declared effective by the SEC | Apr 7, 2016 |
| Final prospectus, with the price | Apr 7, 2016 |
Filings
| Filing | Filed |
|---|---|
| EFFECT · Notice that a registration is effective | Apr 7, 2016 |
| 424B4 · Prospectus | Apr 7, 2016 |
| POS AM · Amendment to an effective registration | Apr 7, 2016 |
| EFFECT · Notice that a registration is effective | Apr 6, 2016 |
| S-1/A · Registration statement, amended | Apr 6, 2016 |
| CORRESP · Letter to the SEC | Apr 4, 2016 |
| CORRESP · Letter to the SEC | Apr 4, 2016 |
| CERTNAS · Nasdaq's certificate of listing | Mar 31, 2016 |
| UPLOAD · Letter from the SEC | Mar 30, 2016 |
| CORRESP · Letter to the SEC | Mar 29, 2016 |
All 22 filings
| Filing | Filed |
|---|---|
| 8-A12B · Registration of shares for listing on an exchange | Mar 28, 2016 |
| S-1/A · Registration statement, amended | Mar 28, 2016 |
| CORRESP · Letter to the SEC | Mar 24, 2016 |
| UPLOAD · Letter from the SEC | Mar 24, 2016 |
| CORRESP · Letter to the SEC | Mar 22, 2016 |
| S-1/A · Registration statement, amended | Mar 14, 2016 |
| S-1/A · Registration statement, amended | Nov 5, 2015 |
| S-1/A · Registration statement, amended | Sep 14, 2015 |
| CORRESP · Letter to the SEC | Jun 24, 2015 |
| S-1 · Registration statement | Jun 16, 2015 |
| UPLOAD · Letter from the SEC | Jun 3, 2015 |
| DRS · Draft registration statement | May 6, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 7, 2016
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 886.0K | 2.33M | 18.7M | 0 | 0 | 3.89M | 5.21M | 4.63M |
| Cost of revenue | 171.7M | 964.0K | 964.0K | 1.96M | 2.00M | 1.62M | 901.0K | |||
| Gross profit | -171.7M | 886.0K | -78.0K | 2.33M | 18.7M | -1.62M | -901.0K | 3.89M | 5.21M | 4.63M |
| Research and development | 171.7M | 162.8M | 89.5M | 58.6M | 57.1M | 59.6M | 64.6M | 36.7M | 22.8M | 18.1M |
| Selling, general and administrative | 47.9M | 45.8M | 39.9M | 28.5M | 27.3M | 21.8M | 17.8M | |||
| Operating income | -209.6M | -208.6M | -242.3M | -84.8M | -65.6M | -81.5M | -80.3M | -45.5M | -27.7M | -21.9M |
| Depreciation and amortization | 0 | 0 | 744.0K | 1.57M | 1.58M | 996.0K | 418.0K | 293.0K | 249.0K | 132.0K |
| EBITDA | -209.6M | -208.6M | -241.6M | -83.2M | -64.1M | -80.5M | -79.9M | -45.2M | -27.4M | -21.8M |
| Income before tax | -155.2M | -208.0M | -338.8M | -84.0M | -65.7M | -80.9M | -78.3M | -44.3M | -27.2M | -21.7M |
| Income tax | -15.0K | 51.0K | -26.0K | -136.0K | 141.0K | 0 | 0 | 0 | 0 | 0 |
| Net income | -155.2M | -208.0M | -338.8M | -83.8M | -65.8M | -80.9M | -78.3M | -44.3M | -27.2M | -21.7M |
| Earnings per share, basic | -1.98 | -3.45 | 13.76 | -24.86 | -25.02 | -1.52 | -2.45 | -2.13 | -1.80 | -2.22 |
| Earnings per share, diluted | 13.76 | -24.86 | -25.02 | -1.52 | -2.45 | -2.13 | -1.80 | -2.22 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 85.7M | 89.4M | 188.9M | 34.9M | 15.1M | 90.1M | 19.3M | 22.5M | 12.8M | 47.7M |
| Short-term investments | 670.8M | 513.7M | 150.4M | 20.8M | 78.0M | 56.2M | 52.7M | 52.1M | 37.5M | 15.8M |
| Receivables | 375.0K | 815.0K | 300.0K | 3.08M | 1.22M | |||||
| Current assets | 777.8M | 608.5M | 341.5M | 62.3M | 98.9M | 149.8M | 74.5M | 76.7M | 55.0M | 66.4M |
| Property, plant and equipment | 0 | 3.22M | 4.55M | 5.64M | 2.38M | 1.02M | 854.0K | 599.0K | ||
| Total assets | 777.8M | 608.5M | 341.9M | 71.1M | 109.9M | 161.6M | 83.2M | 77.7M | 56.1M | 67.1M |
| Accounts payable | 8.90M | 666.0K | 896.0K | 677.0K | 3.32M | 2.25M | 3.15M | 663.0K | 389.0K | 168.0K |
| Current liabilities | 58.7M | 54.1M | 32.0M | 14.7M | 20.1M | 16.4M | 18.4M | 10.2M | 5.63M | 3.96M |
| Total debt | 84.6M | 84.6M | 4.63M | 5.06M | 5.45M | 5.12M | ||||
| Total liabilities | 62.5M | 90.7M | 73.3M | 20.8M | 26.0M | 21.8M | 23.1M | 10.3M | 5.74M | 4.10M |
| Shareholders' equity | 715.2M | 517.8M | 184.0M | 50.3M | 83.9M | 139.8M | 60.1M | 67.4M | 50.3M | 63.0M |
| Shares outstanding | 78.2M | 60.3M | 36.1M | 2.61M | 49.4M | 48.0M | 29.1M | 24.1M | 16.7M | 13.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -169.3M | -157.4M | -99.9M | -80.1M | -53.7M | -75.8M | -65.7M | -32.2M | -24.6M | -18.8M |
| Capital spending | 0 | 0 | 0 | -38.0K | -573.0K | -4.28M | -1.49M | -422.0K | -619.0K | -212.0K |
| Free cash flow | -169.3M | -157.4M | -99.9M | -80.2M | -54.3M | -80.1M | -67.2M | -32.6M | -25.2M | -19.1M |
| Cash from investing | -143.5M | -353.3M | -108.4M | 57.0M | -22.6M | -7.60M | -1.74M | -15.2M | -22.5M | -12.1M |
| Cash from financing | 309.0M | 410.9M | 361.1M | 42.7M | 1.39M | 154.5M | 65.7M | 57.1M | 12.2M | 49.4M |
| Change in cash | -3.70M | -99.8M | 152.8M | 19.4M | -75.0M | 71.2M | -1.71M | 9.64M | -34.9M | 18.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 7, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Oct 6, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Oct 5, 2026 | Offer document | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 1, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 30, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 25, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Jun 26, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 3, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 22, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 16, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 13, 2026 | Results | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 10, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 2, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Feb 27, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 25, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 25, 2026 | Other filings | SEC |
| S-3 · Registration statement | Feb 19, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 19, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 19, 2026 | Results | SEC |
| 10-K · Annual report | Feb 19, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 14, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Oct 14, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 14, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2025 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | Jun 2, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 9, 2025 | Other filings | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 14, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 14, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 14, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 10, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 7, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Mar 5, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 4, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 27, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 8-K · Current report | Nov 19, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 19, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Nov 18, 2024 | Offer document | SEC |
| 10-Q/A · Quarterly report, amended | Nov 18, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 18, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 18, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Nov 18, 2024 | Annual report | SEC |
| 8-K · Current report | Nov 18, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 7, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 25, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Oct 23, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Oct 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 1, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Sep 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 26, 2024 | Other filings | SEC |
| S-3 · Registration statement | Sep 20, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 19, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 13, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 12, 2024 | Other filings | SEC |
| S-3 · Registration statement | Sep 6, 2024 | Offer document | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 7, 2024 | Offer document | SEC |
| 8-K/A · Current report, amended | Aug 7, 2024 | Current report | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 30, 2024 | Current report | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 16, 2024 | Insider trade | SEC |
This page holds 200 of 823 filings. Open Filings
Cap table
Built by 6ix from Spyre Therapeutics, Inc.’s releases · as of Nov 3, 2026
- Common shares
- 94,969,184
- Fully diluted
- 94,983,517
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 94,969,184 | Oct 27, 2026 |
| Options and RSUs | 14,333 | Nov 2, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$95.51 · expire about Nov 2036 |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Oct 27, 2026 | 94,969,184 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Felix Baker Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past) | Director · Feb 23, 2021 – Jun 8, 2021 · Past |
| Julian Baker Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past) | Director · Feb 23, 2021 – Jun 8, 2021 · Past |
| Peter Harwin Other companies: Alaunos Therapeutics, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Oct 13, 2026); Damora Therapeutics, Inc. (Chairman of the Board · Since at least Nov 10, 2025); Crescent Biopharma, Inc. (Chair of Board · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Jan 22, 2024 · Past); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past) | Director · Since at least Jun 22, 2023 |
| Alison Frances Lawton Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); Dianthus Therapeutics, Inc. (Director · Since at least Dec 22, 2020); X4 Pharmaceuticals, Inc. (Director · Oct 5, 2020 – Jun 10, 2024 · Past); Kaleido Biosciences, Inc. (See Remarks, Director · Feb 27, 2019 – Apr 15, 2020 · Past); CoLucid Pharmaceuticals Inc (Director · Mar 11, 2016 – Mar 1, 2017 · Past); Tempest Therapeutics, Inc. (Chief Operating Officer · Jan 21, 2013 – Jun 7, 2013 · Past); Verastem, Inc. (Director · Nov 26, 2012 – Jun 21, 2019 · Past); Cubist Pharmaceuticals Inc (Director · Feb 15, 2012 – Jan 21, 2015 · Past) | Director · Dec 15, 2020 – Jun 22, 2023 · Past |
| Tomas Kiselak Other companies: Cyclerion Therapeutics, Inc. (Chairman · Since at least Apr 1, 2026); Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Viridian Therapeutics, Inc. (Director · Since at least Oct 27, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Sep 27, 2024 · Past) | Director · Since at least Jun 22, 2023 |
| Mark McKenna Other companies: Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Jul 16, 2024); Apogee Therapeutics, Inc. (Director · Since at least Aug 17, 2023); Freenome, Inc. (Director · Jun 11, 2024 – Jun 11, 2024 · Past); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Prometheus Biosciences Inc (Chairman, President and CEO, Director · Mar 11, 2021 – Jun 16, 2023 · Past); Bausch Health Companies Inc. (President, Salix · Aug 2, 2018 – Aug 19, 2019 · Past) | Board Member · Since at least Feb 1, 2024 |
| Suzanne L. Bruhn Other companies: Definium Therapeutics, Inc. (Director · Since at least Aug 11, 2022); Vigil Neuroscience Inc (Director · Since at least Jul 27, 2022); Pliant Therapeutics, Inc. (Director · Since at least Jun 2, 2020); Travere Therapeutics, Inc. (Director · Since at least Apr 8, 2020); Avalo Therapeutics, Inc. (Director · Apr 24, 2020 – Nov 10, 2021 · Past); Novelion Therapeutics Inc (Director · Oct 1, 2017 – Aug 9, 2018 · Past); Raptor Pharmaceutical Corp (Director · Sep 25, 2012 – Oct 24, 2016 · Past) | Director · Feb 15, 2017 – Jun 8, 2020 · Past |
| Laurie Stelzer Other companies: MBX Biosciences, Inc. (Director · Since at least Jan 20, 2026); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); PMV Pharmaceuticals, Inc. (Chair, Board of Directors · Since at least Sep 24, 2020); Arena Pharmaceuticals Inc (EVP & Chief Financial Officer · Mar 16, 2020 – Mar 11, 2022 · Past); Surface Oncology Inc (Director · Apr 18, 2018 – Jun 8, 2022 · Past); Halozyme Therapeutics, Inc. (SVP, Chief Financial Officer · Jun 15, 2015 – Feb 22, 2020 · Past) | Chair of the Audit Committee · Since at least Nov 22, 2023 |
| V Bryan Lawlis Other companies: Sutro Biopharma, Inc. (Director · Sep 26, 2018 – Sep 26, 2018 · Past); Coherus Oncology, Inc. (Director · Nov 6, 2014 – Jan 11, 2021 · Past); Humanigen Inc (Director · Aug 7, 2013 – Jun 18, 2014 · Past); BioMarin Pharmaceutical Inc. (Director · May 8, 2012 – May 23, 2023 · Past); Geron Corporation (Director · Mar 13, 2012 – May 21, 2025 · Past) | Director · Jul 13, 2018 – Jun 7, 2022 · Past |
| Cameron Turtle Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Mar 23, 2026); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); BridgeBio Pharma, Inc. (See Remarks · Jun 27, 2019 – Dec 28, 2020 · Past); Eidos Therapeutics Inc (Chief Business Officer · Nov 5, 2018 – Jan 26, 2021 · Past) | Chief Executive Officer · Since at least Jun 22, 2023 |
All 43 people
| Person | Seat |
|---|---|
| Ivana Magovčević-Liebisch Other companies: Quanterix Corporation (Director · Since at least Oct 2, 2024); Acrivon Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Vigil Neuroscience Inc (President and CEO, Director · Since at least Jan 6, 2022); Absci Corporation (Director · Jul 21, 2021 – Jun 8, 2022 · Past) | Director · Jun 8, 2021 – Jun 22, 2023 · Past |
| Sandesh Mahatme Other companies: Vor Biopharma Inc. (CFO · Since at least Jul 9, 2025); CRISPR Therapeutics AG (Director · Since at least May 30, 2024); Flexion Therapeutics Inc (Director · Jul 22, 2014 – Jun 10, 2020 · Past); Sarepta Therapeutics, Inc. (EVP, CFO & CBO · Nov 5, 2012 – May 11, 2020 · Past) | Director · Apr 6, 2016 – Jun 7, 2022 · Past |
| Anthony G Quinn Other companies: Generation Bio Co (Director · Since at least Jun 11, 2020); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past); Synageva BioPharma Corp (EVP, CMO, & Head of R&D · Nov 2, 2011 – Jun 22, 2015 · Past) | President & CEO, Director · Apr 6, 2016 – Mar 16, 2022 · Past |
| Armen Shanafelt Other companies: Surface Oncology Inc (Director · Apr 18, 2018 – Jun 8, 2022 · Past); Rein Therapeutics, Inc. (Director · Jun 28, 2017 – Jun 21, 2018 · Past); Protagonist Therapeutics, Inc. (Director · Aug 10, 2016 – May 29, 2018 · Past) | Director · Apr 6, 2016 – Jun 7, 2022 · Past |
| Jeffrey Albers Other companies: Kymera Therapeutics, Inc. (Director · Since at least Aug 20, 2020); Blueprint Medicines Corp (Director · Since at least Apr 30, 2015); Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past) | Director · Since at least Nov 22, 2023 |
| Marcio Souza Other companies: Praxis Precision Medicines, Inc. (President & Chief Executive Officer · Since at least Oct 15, 2020); ClearPoint Neuro Inc. (Director · May 17, 2019 – May 17, 2019 · Past); PTC Therapeutics, Inc. (Chief Operating Officer · May 31, 2017 – Feb 10, 2020 · Past) | Director · Jun 18, 2021 – Aug 25, 2022 · Past |
| Michael Henderson Other companies: Apogee Therapeutics, Inc. (Chief Executive Officer · Since at least Jul 13, 2023); ARYA Sciences Acquisition IV Corp (Director · Feb 25, 2021 – Jul 31, 2024 · Past); BridgeBio Pharma, Inc. (Chief Business Officer · Jun 27, 2019 – Dec 15, 2020 · Past) | Board Member · Since at least Jun 22, 2023 |
| Russell J. Cox Other companies: Gossamer Bio, Inc. (Director · Since at least Feb 7, 2019); Immunic, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 11, 2019 · Past); Jazz Pharmaceuticals plc (EVP & COO · Feb 8, 2011 – Dec 11, 2017 · Past) | Director · Apr 6, 2016 – Jun 22, 2023 · Past |
| Sandra Milligan Other companies: Gossamer Bio, Inc. (Director · Since at least Jun 10, 2021); Aspira Women's Health Inc. (Interim CEO & President · Apr 1, 2024 – Dec 31, 2024 · Past); Organon & Co. (Head of Research & Development · Jun 2, 2021 – May 4, 2023 · Past) | Chair of the Nominating and Corporate Governance Committee · Since at least May 14, 2024 |
| Heidy King-Jones Other companies: Provention Bio Inc (Chief Legal Officer · Aug 3, 2020 – Apr 27, 2023 · Past); Axcella Health Inc (General Counsel, SVP Legal · Nov 13, 2019 – Dec 18, 2019 · Past) | Chief Legal Officer and Corporate Secretary · Since at least Sep 1, 2023 |
| Hunter Smith Other companies: Rhythm Pharmaceuticals, Inc. (Chief Financial Officer and Treasurer · Since at least Oct 4, 2017); Genesee & Wyoming Inc (Director · Jun 30, 2015 – Dec 30, 2019 · Past) | Director · Nov 12, 2021 – Jun 22, 2023 · Past |
| James Kastenmayer Other companies: ArriVent BioPharma, Inc. (General Counsel · Since at least Jan 25, 2024); Viela Bio Inc (General Counsel · Jan 6, 2020 – Mar 15, 2021 · Past) | General Counsel · Aug 23, 2022 – Feb 23, 2023 · Past |
| Madduri Ravin Rao Other companies: Autolus Therapeutics plc (Director · Since at least Mar 18, 2026); DBV Technologies SA (Director · May 19, 2021 – Jun 10, 2021 · Past) | Chief Medical Officer · Nov 1, 2019 – Feb 14, 2020 · Past |
| Steven Weber Other companies: Pulse Biosciences, Inc (Principal Accounting Officer · Since at least Jul 14, 2025); IGM Biosciences Inc (PRINCIPAL ACCOUNTING OFFICER · Since at least May 25, 2022) | VP, Controller&Princ Acctg Off · Feb 2, 2021 – Feb 17, 2022 · Past |
| Aaron Schuchart Other companies: Lumos Pharma Inc (Chief Business Officer · May 19, 2021 – Dec 12, 2024 · Past) | Chief Business Officer · May 22, 2017 – Feb 28, 2019 · Past |
| Charles N York II Other companies: Day One Biopharmaceuticals Inc (COO and CFO · Since at least May 26, 2021) | Chief Financial Officer and VP · Apr 6, 2016 – Feb 14, 2020 · Past |
| James Wooldridge Other companies: Checkmate Pharmaceuticals Inc (Chief Medical Officer · Aug 6, 2020 – May 31, 2022 · Past) | Chief Medical Officer · Jul 10, 2017 – Feb 28, 2019 · Past |
| Jeff Marc Goldberg Other companies: Akcea Therapeutics Inc (Chief Operating Officer · Jan 2, 2018 – Sep 26, 2019 · Past) | President and CEO, Director · Nov 29, 2022 – Nov 29, 2022 · Past |
| Michael Conick Hanley Jr Other companies: Alto Neuroscience, Inc. (CHIEF OPERATING OFFICER · Since at least May 20, 2024) | Chief Business Officer · Oct 21, 2019 – Feb 23, 2023 · Past |
| Sandra Rojas-Caro Other companies: NeuBase Therapeutics Inc (Chief Medical Officer · May 24, 2021 – Jan 24, 2022 · Past) | Chief Medical Officer · May 17, 2016 – May 17, 2016 · Past |
| Scott L Burrows Other companies: Arcutis Biotherapeutics, Inc. (Chief Financial Officer · Apr 1, 2021 – Mar 6, 2023 · Past) | Chief Financial Officer · Since at least Sep 1, 2023 |
| David George Lowe | CEO and President, Director · Apr 6, 2016 – Mar 20, 2017 · Past |
| Eric McIntyre | SVP of Finance and Investor Relations · Since at least Nov 3, 2026 |
| George Georgiou | Director · Apr 6, 2016 – Aug 13, 2018 · Past |
| Henry Hebel | VP, Product Development · Apr 6, 2016 – Mar 20, 2017 · Past |
| Jeff Albers | Chair of the Compensation Committee · Since at least Aug 10, 2026 |
| Jonathan Alspaugh | President and CFO · Jul 6, 2021 – Jun 22, 2023 · Past |
| Joseph E Tyler | VP, Manufacturing · Apr 6, 2016 – Aug 22, 2017 · Past |
| Leslie Sloan | Chief Operating Officer · Mar 6, 2019 – Aug 23, 2022 · Past |
| Linda L Neuman | Chief Medical Officer · Nov 14, 2022 – Feb 23, 2023 · Past |
| Sara Brownstein | Director · Feb 23, 2021 – Feb 23, 2021 · Past |
| Scott W Rowlinson | VP, Research · Apr 6, 2016 – Aug 22, 2017 · Past |
| Sheldon Sloan | Chief Medical Officer · Since at least Oct 1, 2024 |
Log in to ask 6ix AI your own questions about Spyre Therapeutics, Inc.